The impact of atopic dermatitis on sexual health

Miséry, Laurent; Sénéschal, Julien; Réguiai, Z.; Merhand, Stéphanie; Héas, Stéphane; Huet, F.; Taïeb, C.; Ezzedine, Khaled

doi:10.1111/jdv.15223

Cited by 43 publications

(49 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings urge the need to incorporate patients' perceptions in AD assessment tools, such as the Atopic Dermatitis Control Tool [21]. Although our study did not identify all patient-reported consequences of AD, such as the known impact of AD on sexual health [22], our qualitative approach has provided an understanding of patient perceptions and the underlying range of physical and emotional consequences of AD, which can inform shared decision-making. These findings suggest the need for broader assessment of the impact of AD on patients' lives.…”

Section: Ad Atopic Dermatitismentioning

confidence: 96%

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study

Falissard

Simpson

Guttman‐Yassky

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Section: Ad Atopic Dermatitismentioning

confidence: 96%

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study

Falissard

Simpson

Guttman‐Yassky

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…8,9 Indeed, only a minority (5%) experience improvement in the signs and symptoms of their skin disease during pregnancy. [4][5][6] AEP presents with highly variable clinical manifestations. The differential diagnosis is quite broad and may include contact dermatitis, pruritic urticarial papules and plaques of pregnancy, drug eruptions, polymorphic eruption of pregnancy, pemphigoid gestationis and mycosis fungoides.…”

Section: Clinical Presentation Of Ad In Pregnant Womenmentioning

confidence: 99%

“…3 This may result in inadequate control of AD, potentially leading to flares and infections, and may have a detrimental effect on the health of women during pregnancy as well as a serious impact on sexual health. 5 Recently, in a critical appraisal of the topic, the evidence of pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid was summarized; however, the literature was very sparse and mainly of an observational character. 6 In the 2015 European Task Force on Atopic Dermatitis (ETFAD) position paper on treatment of AD, we listed systemic agents that were absolutely contraindicated during pregnancy, including methotrexate, alitretionine and mycophenolate mofetil, whereas cyclosporine A and azathioprine were recommended as drugs that could be used in certain instances.…”

Section: Introductionmentioning

confidence: 99%

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Vestergaard

Wollenberg

Barbarot

et al. 2019

Acad Dermatol Venereol

Self Cite

173

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up‐to‐date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

show abstract

“…In the United States, AD was associated with higher rates of anxiety, depression, lost productivity, activity impairment and poorer health‐related quality of life compared with patients without AD . In France, an altered quality of life was found in patients who had visible areas involvement . Moreover, the same study showed AD had an impact on patients’ sexual health by affecting their sexual desire.…”

Section: Introductionmentioning

confidence: 92%

Importance of out‐of‐pocket costs for adult patients with atopic dermatitis in France

Launois

Ezzedine

Cabout

et al. 2019

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Background Currently, few studies investigated the economic burden of atopic dermatitis (AD) in adult patients and specifically the estimation of out-of-pocket costs. Patients with skin disorders primarily use comfort care to ease dryness, itch or pain, and the costs of comfort care are not subject to any reimbursement from mandatory or complementary insurance.Objective The purpose of this study was to measure the medical and non-medical expenses paid by the patient.Methods Eczema Cohort Longitudinal Adults was a non-interventional study that aimed to assess the burden of AD in terms of quality of life and financial consequences. A self-assessment questionnaire was distributed to adult patients who were cared in four French hospitals. Patients were asked to list the resources consumed for the treatment of AD during the last 12 months and to estimate the corresponding amount of money they had to pay out of their own pockets.The severity of AD was subjected to a stratification based on the PO-SCORAD score.Results A total of 1024 patients answered the questionnaire: 31.9% with severe AD, 40.4% with moderate AD and 27.6% with mild AD. The mean annual out-of-pocket cost was €462.1 for severe AD and €247.4 for moderate AD. Emollients were the most commonly used product: 74.4% for an average out-of-pocket cost of €151.4. The out-of-pocket costs increased significantly with the severity: 27% of patients with severe AD declared having bought specially textured clothes, while 19% of patients with moderate AD reported the same. The corresponding mean out-of-pocket costs were €162 and €91, respectively.Conclusion The amount of out-of-pocket costs for patients with AD for essential medical and non-medical expenses is relatively high, compared to the average out-of-pocket cost for French households. Integration of these essential resources into the list of reimbursed products and services appears necessary for a better coverage of AD.

show abstract

The impact of atopic dermatitis on sexual health

Abstract: The results of this study are substantial and clearly demonstrate the deep impact of AD on sexual health, its relationship with disease-related burden and alterations to quality of life. Psychosociological as well as neurosensory phenomena could help to understand these data.

Cited by 43 publications

References 25 publications

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study

Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

Importance of out‐of‐pocket costs for adult patients with atopic dermatitis in France

Contact Info

Product

Resources

About